Biomarkers: Technologies and Global Markets
Report Highlights
The global biomarkers market is expected to grow from $29.3 billion in 2013 to $53.6 billion in 2018, a compound annual growth rate (CAGR) of 12.8%.
Report Includes
- An overview of the global market for biomarkers.
- Analyses of global market trends, with data from 2012 and 2013, and projections of compound annual growth rates (CAGRs) through 2018.
- Assessments of companies poised to introduce products during the forecast period and discussion on how these introductions will change the face of the competitive environment.
- A range of information from detailed product analyses within disease subsegments to overall industry trends.
- A look at how market growth is expected in emerging geographies, driven by the growing middle class in emerging countries such as India, China, Brazil, and Russia.
- Comprehensive profiles of manufacturers of leading products as well as biotechnology companies with novel products in development.
Report Scope
Current and projected product forecasts during the forecast period (2013 to 2018) are discussed. In addition, new products approved in 2012 and 2013 by the FDA, and those products expected to be approved within the forecast period, are projected. Figures are estimated for 2013, except where actual results have been reported, due to the timing of the release of the report. For all areas, including very large markets segments such as infectious disease and cardiovascular, specific mechanisms of action are discussed in detail. Market figures include the bundled value of the drug and the biomarker as it is impossible to quantitate the composite values of each.
The report includes an analysis of leading and emerging competitors in the current worldwide biomarkers market. Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define their specific product strategies. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products and technologies are influencing the current standard of care. Detailed profiles of current market leaders are discussed, as well as companies with innovative products poised to advance within the forecast period.
Market figures are based on revenues at the manufacturers’ level and are projected at 2013-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products and projected changes in the prevalence, diagnosis and scripting rates for certain diseases.
Included in this report are forecasts by product, product category and by company from 2013 through 2018. The study is arranged to offer an overview of the biomarkers market accompanied by product, company, geography and mechanism of action with forecasts broken down and covered by geographic region or country. Virtually the entire globe is covered to include prevalence data for each disease subsegment.
Excluded from this report are over-the-counter (OTC) medications and other consumables that do not require a physician’s prescription.
Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.
All market share data presented is on a global basis, unless specifically noted.
Analyst Credentials
Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy, where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development. Jackson Highsmith is a pseudonym of the author.
Report Highlights
In 2010, the total global market for biomarkers was an estimated $13.5 billion and is expected to grow to nearly $33.3 billion by the end of 2015 at a 5-year compound annual growth rate (CAGR) of 19.8%.
Report Highlights
-
The global market for biomarkers increased from $4.8 billion in 2006 to an estimated $5.6 billion by the end of 2007. It should reach $12.8 billion by 2012, a compound annual growth rate (CAGR) of 18%.
-
Global revenues for biomarker discovery technologies tailored to drug discovery, preclinical studies of drug development and diagnostics research applications accounted for 47.9% of the total market in 2007. Their value is projected to grow at a CAGR of 16.9% and is expected to reach a little less than $6 billion in 2012.
-
The use of biomarkers in oncology therapeutics is likely to be one of the foremost priorities in clinical trials in the next 3 to 7 years followed by cardiovascular applications.